Attendee search 

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology.  The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies.  Astex Pharmaceuticals developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.

 

For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.

Shield Therapeutics is an independent specialty pharmaceutical company, founded in 2008 with operations in Europe & US. Focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need Shield is led by Carl Sterritt, Chief Executive Officer, an experienced senior pharmaceutical executive with a track record of successful development and commercialisation of pharmaceuticals Shield has successfully raised ~$34m to fund the development of ST10 and PT20 (developed through Phosphate Therapeutics) Lead asset – ST10: Simplifying iron replacement therapy ·         Novel oral iron-based therapy with strong IPR ·         Potential to be the first simple effective oral therapy for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) and non-dialysis dependant chronic kidney disease (CKD) ·         Currently in Phase III trials in patients with IDA in IBD ·         Results are expected to form the basis of a marketing authorisation application (“MAA”) in 2013.  If approved, product commercialisation could commence in 2014 ·         CKD-IDA trials to follow in 2012-2013 ·         Targets potential addressable market of $5bn, with immediate IV market currently reaching  >$1bn pa   PT20: for the treatment of hyperphosphataemia ·         Novel phosphate binder to treat hyperphosphataemia in patients with pre-dialysis and dialysis-dependent CKD ·         In-licensed from Medical Research Council - agreement signed in Q3-11 ·         Early data from in vitro and in vivo trials suggests higher specificity and efficacy than current market leaders and favourable opinion received from UK-MHRA for progression to Phase II clinical trials ·         Approximately 90% of patients with kidney failure require phosphate binder therapy at some point ·         Current market size >$1bn/yr